New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. | A quantum ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...

Viridian Therapeutics unveiled mixed results Tuesday for its experimental eye disease treatment, a potential rival to Amgen's ...

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

Thousand Oaks pharma giant Amgen Inc. is making a series of C-suite changes, triggered by the retirement announcement of ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ‌citing ⁠a lack of proven ...

Amgen's two patent applications purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism fail to satisfy the Patent Act's enablement clause, ...